Avidity Partners Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-85,700
| Closed | -$9.48M | – | 77 |
|
|
2025
Q1 | $9.48M | Sell |
85,700
-134,700
| -61% | -$17.1M | 1.95% | 18 |
|
|
2024
Q4 | $30.1M | Sell |
220,400
-239,600
| -52% | -$29.6M | 3% | 9 |
|
|
2024
Q3 | $53M | Sell |
460,000
-31,000
| -6% | -$4.25M | 2.7% | 7 |
|
|
2024
Q2 | $67.6M | Sell |
491,000
-45,500
| -8% | -$6.24M | 2.87% | 8 |
|
|
2024
Q1 | $74M | Sell |
536,500
-121,500
| -18% | -$16.6M | 2.63% | 8 |
|
|
2023
Q4 | $86.7M | Buy |
658,000
+5,900
| +0.9% | +$679K | 3.32% | 6 |
|
|
2023
Q3 | $73.4M | Sell |
652,100
-13,216
| -2% | -$1.39M | 2.95% | 4 |
|
|
2023
Q2 | $62.7M | Sell |
665,316
-150,384
| -18% | -$14.7M | 2.19% | 12 |
|
|
2023
Q1 | $82.6M | Sell |
815,700
-964,300
| -54% | -$100M | 2.74% | 12 |
|
|
2022
Q4 | $213M | Sell |
1,780,000
-75,700
| -4% | -$8.87M | 4.97% | 4 |
|
|
2022
Q3 | $197M | Buy |
1,855,700
+388,100
| +26% | +$39.4M | 4.29% | 4 |
|
|
2022
Q2 | $143M | Buy |
1,467,600
+307,600
| +27% | +$28.4M | 3.28% | 11 |
|
|
2022
Q1 | $109M | Sell |
1,160,000
-100,000
| -8% | -$8.47M | 2.41% | 17 |
|
|
2021
Q4 | $107M | Buy |
1,260,000
+411,100
| +48% | +$37.8M | 2.28% | 15 |
|
|
2021
Q3 | $81.4M | Buy |
848,900
+167,900
| +25% | +$15.9M | 2.08% | 16 |
|
|
2021
Q2 | $66.3M | Buy |
681,000
+159,600
| +31% | +$15.3M | 1.79% | 16 |
|
|
2021
Q1 | $50.7M | Buy |
521,400
+221,400
| +74% | +$23.2M | 1.41% | 26 |
|
|
2020
Q4 | $28.8M | Buy |
+300,000
| New | +$29M | 0.97% | 39 |
|
|
2020
Q3 | – | Sell |
-185,100
| Closed | -$22.6M | – | 80 |
|
|
2020
Q2 | $22.6M | Buy |
185,100
+87,100
| +89% | +$9.63M | 1.45% | 25 |
|
|
2020
Q1 | $8.48M | Buy |
98,000
+65,000
| +197% | +$6.36M | 1.22% | 31 |
|
|
2019
Q4 | $3.55M | Buy |
+33,000
| New | +$3.46M | 2.24% | 24 |
|
Other funds holding NBIX
